Anixa Biosciences
ANIX
13 hedge funds and large institutions have $4.12M invested in Anixa Biosciences in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 2 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
55% more capital invested
Capital invested by funds: $2.65M → $4.12M (+$1.47M)
0.02% more ownership
Funds ownership: 4.73% → 4.75% (+0.02%)
13% less funds holding
Funds holding: 15 → 13 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$352K |
| 2 |
BlackRock
New York
|
+$24.7K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$24.5K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$18.7K |
| 5 |
JP Morgan Chase
New York
|
+$8.82K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$265K |
| 2 |
CAM
Concorde Asset Management
Ann Arbor,
Michigan
|
-$30K |
| 3 |
Bank of New York Mellon
New York
|
-$6.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.83K |
| 5 |
Morgan Stanley
New York
|
-$3.55K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $2.68M | +$2.64K | +700 | +0.1% |
|
|
2
UBS Group
Zurich,
Switzerland
| $644K | +$352K | +93,550 | +207% |
|
|
3
BlackRock
New York
| $242K | +$24.7K | +6,565 | +14% |
|
|
4
Bank of New York Mellon
New York
| $194K | -$6.2K | -1,646 | -4% |
|
|
5
Northern Trust
Chicago,
Illinois
| $193K | +$18.7K | +4,960 | +14% |
|
|
SBH
6
Segall Bryant & Hamill
Chicago,
Illinois
| $81K | – | – | – |
|
|
7
Wells Fargo
San Francisco,
California
| $35K | +$24.5K | +6,520 | +724% |
|
8
Bank of America
Charlotte,
North Carolina
| $21K | +$1.62K | +430 | +11% |
|
|
9
JP Morgan Chase
New York
| $15K | +$8.82K | +2,342 | +261% |
|
|
10
Morgan Stanley
New York
| $7K | -$3.55K | -944 | -36% |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $5K | -$5.83K | -1,547 | -58% |
|
|
12
Geode Capital Management
Boston,
Massachusetts
| – | -$265K | -87,602 | Closed |
|
|
CAM
13
Concorde Asset Management
Ann Arbor,
Michigan
| – | -$30K | -10,000 | Closed |
|
ANIX Hedge Fund Activity: Q3 2018 in Review
13 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q3 2018, worth a combined $4.12M — up 55% from $2.65M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ANIX and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was UBS Group, adding an estimated $352K. The largest seller was Geode Capital Management, exiting entirely with an estimated $265K sold.
- 13 institutional investors held Anixa Biosciences (ANIX) as of Q3 2018, down from 15 in Q2 2018.
- Funds reported $4.12M of Anixa Biosciences stock for Q3 2018, up 55% quarter-over-quarter.
- 0 funds opened new Anixa Biosciences positions in Q3 2018 and 2 closed out, a net change of -2 holders.
- The largest Anixa Biosciences buyer in Q3 2018 was UBS Group, an estimated $352K added.
- The largest Anixa Biosciences seller in Q3 2018 was Geode Capital Management, an estimated $265K sold.
Based on aggregated 13F filings for Q3 2018.